Target intelligence / Profile preview

Vibrio cholerae O1 lipopolysaccharide antigen

Molecular classification
Other (Bacterial cell surface antigen / polysaccharide component of lipopolysaccharide)
01

Overview

The Vibrio cholerae O1 lipopolysaccharide antigen (O1 LPS antigen) is a surface carbohydrate structure and the primary serogroup-defining antigen of *V. cholerae* O1, the strain responsible for most cholera pandemics. The O1 LPS antigen comprises a homopolymer of perosamine residues as the O-specific polysaccharide (OSP) attached to the core oligosaccharide and lipid A of the bacterial outer membrane[2][4][5]. It determines O1 serogroup and serotype (Ogawa, Inaba, Hikojima) specificity, crucial for virulence, colonization, and immune recognition[4][7]. The O1 antigen is the main target for protective antibody responses after infection and vaccination, providing the rationale for current vaccine strategies[5][6]. It is also targeted by bacteriophages and subject to phase variation and serotype switching, allowing immune evasion and adaptation within hosts or epidemics[1][7]. Although not a classical drug target for small molecules, it is under active investigation for vaccine development and as a biomarker for immune protection or exposure[6]. Key features: - **Structural class:** O-specific polysaccharide component of LPS, attached to outer membrane lipid A[2][3][4]. - **Virulence:** Essential for host colonization, infectiousness, and protection against bacteriophage predation[1][4]. - **Vaccine target:** Main antigen in current and in-development cholera vaccines[5][6]. - **Serotype specificity:** Variation in O1 antigen determines serotype (Ogawa, Inaba, Hikojima), based on methylation status of terminal perosamine[4][5][7]. - **Immunogenicity:** Induces robust IgG, IgM, and IgA responses, closely correlating with vibriocidal antibody titers, serving as correlates of protection[6]. - **Antigenic variation:** Phase variable genes (e.g., manA, wbeL, rfbT) control biosynthesis and enable intra-strain O1 expression diversity, affecting vaccine efficacy and immune escape potential[1][4][7].

Other names
Vibrio cholerae O1 LPS antigenV. cholerae O1 O-antigenV. cholerae O1 O-specific polysaccharideV. cholerae O1 OSP
02

Mechanism of action

Antibody neutralization; Bacteriophage lysis

03

Biological functions

Immune response (elicits antibody responses and is a major antigen recognized by immune system)Pathogenesis (crucial for virulence and host colonization)Phage interaction (target of lytic bacteriophages)
04

Disease associations

Infection (major determinant of cholera infections and a critical virulence factor for *Vibrio cholerae*)
05

Safety considerations

Antigenic variability (phase variation and serotype switching may impact efficacy of vaccines and antibody-based diagnostics or therapies)[1][4][7]Risk of immune escape (bacterial populations may evade immune detection by altering O-antigen structure)[1][4]
06

Biomarkers

Serum anti-O1 LPS or anti-O1 OSP antibodies (used to monitor immunity and vaccine responses)[6]Vibriocidal antibody titers (biomarker for protective immunity and response to infection/vaccination)[6]

Beyond the preview

Go deeper on Vibrio cholerae O1 lipopolysaccharide antigen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vibrio cholerae O1 lipopolysaccharide antigen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call